Heartflow carries 98% product concentration in a single offering, deeply negative free cash flow, and a risk/reward of roughly 0.3-to-1 against you at the current price — the combination of structural quality concerns, failed earnings delivery over the prior two quarters before recent recovery, and a bearish options posture makes the setup difficult to justify as a new or expanded position.
Thesis pillars
- Negative Free Cash Flow Sustainability↑Improving
- Single Product Concentration Risk↑Improving
- Growth Without Investable Quality↑Improving
- +1 more pillar — see the Why tab for full reasoning
Heartflow, Inc. (HTFL) Stock Analysis
Healthcare · Health Information Services
Sell if holding. Analyst target reached at $49.75 — A.R:R is negative (-1.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Heartflow FFRCT Analysis (98.0%).
Heartflow provides AI-powered software that analyzes coronary CT angiography (CCTA) scans to non-invasively diagnose coronary artery disease, with the platform deployed across more than 1,465 U.S. hospital and outpatient accounts as of December 31, 2025. Revenue is generated on... Read more
Sell if holding. Analyst target reached at $49.75 — A.R:R is negative (-1.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Heartflow FFRCT Analysis (98.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Heartflow, Inc.
About Heartflow, Inc.
Heartflow FFRCT Analysis accounted for 98% of Heartflow, Inc.'s total revenue as of December 31, 2025, with the Heartflow Platform deployed across more than 1,465 U.S. hospital and outpatient accounts and used to assess CAD in 219,000 patients during 2025. Net losses totaled $116.8 million in fiscal 2025 and $96.4 million in 2024, with an accumulated deficit of $1.1 billion as of December 31, 2025, reflecting ongoing investment in commercial adoption ahead of profitability.
Heartflow generates revenue on a pay-per-analysis basis each time a physician orders Heartflow FFRCT Analysis or Heartflow Plaque Analysis from a CCTA scan transmitted to its cloud platform. FFRCT Analysis carries a dedicated Category I CPT code effective January 1, 2024, with established coverage representing approximately 99% of covered U.S. lives; Heartflow Plaque Analysis—its second commercial product, which entered limited market education in mid-2023—obtained a Category I CPT code effective January 1, 2026, with coverage from five of seven Medicare Administrative Contractors representing approximately 75% of covered lives and commercial payer coverage from Aetna, Cigna, and United Healthcare beginning October 2025. The company competes against traditional non-invasive cardiac tests from GE Healthcare, Siemens Healthineers, and Philips, as well as earlier-stage AI-based CCTA analysis platforms including Cleerly and Elucid Bioimaging. Average sales price in 2025 was pressured by customer volume rebate contracts, a trend the company expects to continue in the near term.
Show full overview
CMS reimbursement policy is the most specifically dated operational risk in the filing. In July 2025, CMS issued the proposed 2026 Outpatient Prospective Payment System rule, which if finalized as proposed could result in a reduction of up to 15% in the Medicare reimbursement rate for the clinical APC that includes Heartflow FFRCT Analysis. Because CMS payment levels often anchor commercial payer rates, a finalized reduction may impact private insurer reimbursement as well. The 10-K acknowledges that whether the proposed reduction would be finalized, modified, or reversed to 2025 levels remained unresolved at filing, making the Q4 2025 OPPS final rule publication the single most clearly dated binary rate catalyst for revenue per analysis.
See also: Healthcare · Health Information Services
From Heartflow, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-08-22Recent Developments — Heartflow, Inc.
Latest news
- NEWS Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 22,562 Shares - MarketBeat — MarketBeat neutral
- NEWS Why is Heartflow stock surging today? - Investing.com — Investing.com positive
- NEWS HEARTFLOW ($HTFL) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative — Quiver Quantitative positive
- NEWS HEARTFLOW ($HTFL) Releases Q2 2026 Earnings, Stock Rises - quiverquant.com — quiverquant.com positive
- NEWS HeartFlow: An Impressive MedTech Growth Play (NASDAQ:HTFL) - Seeking Alpha — Seeking Alpha positive
Generated 2026-08-23T00:51:55Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductHeartflow FFRCT Analysis98%10-K Item 1A: 'our Heartflow FFRCT Analysis represented 98% of our total revenue'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $49.75 — A.R:R is negative (-1.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Heartflow FFRCT Analysis (98.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $46.27. Score 5.3/10, moderate confidence.
Take-profit target: $57.21 (-23.9% upside). Prior stop was $46.27. Stop-loss: $46.27.
Concentration risk — Product: Heartflow FFRCT Analysis (98.0%); Analyst target reached - limited upside remaining; Near 52-week high (1.4% away).
Heartflow, Inc. trades at a P/E of N/A (forward -188.3). TrendMatrix value score: 1.8/10. Verdict: Sell.
15 analysts cover HTFL with a consensus score of 4.2/5. Average price target: $44.
What does Heartflow, Inc. do?Heartflow provides AI-powered software that analyzes coronary CT angiography (CCTA) scans to non-invasively diagnose...
Heartflow provides AI-powered software that analyzes coronary CT angiography (CCTA) scans to non-invasively diagnose coronary artery disease, with the platform deployed across more than 1,465 U.S. hospital and outpatient accounts as of December 31, 2025. Revenue is generated on a pay-per-analysis basis, with Heartflow FFRCT Analysis accounting for 98% of total revenue and covered under a Category I CPT code representing approximately 99% of covered U.S. lives.